A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response - Wikidata - awgldk - TriplyDB

A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response

A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response

http://www.wikidata.org/entity/Q35182795

about

Updates in Therapy for Advanced Melanoma Trial Watch: Adoptive cell transfer for oncological indications T-Cell Therapy: Options for Infectious Diseases Perspectives in the treatment of pancreatic adenocarcinoma Adoptive T-cell therapy for cancer: The era of engineered T cells Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer Vaccination Recent advances in T-cell engineering for use in immunotherapy T-cell receptor gene therapy--ready to go viral?Cancer-testis antigen SLLP1 represents a promising target for the immunotherapy of multiple myeloma T-Cell Receptor-Engineered Cells for the Treatment of Hematologic Malignancies.Specific Etiologies Associated With the Multiple Organ Dysfunction Syndrome in Children: Part 1.T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.Direct tumor recognition by a human CD4(+) T-cell subset potently mediates tumor growth inhibition and orchestrates anti-tumor immune responses.Inclusion of Strep-tag II in design of antigen receptors for T-cell immunotherapy.Neoantigens in cancer immunotherapy.NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma.Adoptive T-cell therapy for cancer in the United kingdom: a review of activity for the British Society of Gene and Cell Therapy annual meeting 2015.Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer.Toxicities Associated With Adoptive T-Cell Transfer for Cancer.Landscape of Tumor Antigens in T Cell Immunotherapy.Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer.Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors.MAGE-A is More Highly Expressed Than NY-ESO-1 in a Systematic Immunohistochemical Analysis of 3668 Cases.Cancer immunotherapy targeting neoantigens.Molecular Pathways: Breaking the Epithelial Cancer Barrier for Chimeric Antigen Receptor and T-cell Receptor Gene Therapy Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy.Isolation and Characterization of an HLA-DPB1*04: 01-restricted MAGE-A3 T-Cell Receptor for Cancer Immunotherapy Establishment and characterization of a new human myxoid liposarcoma cell line (DL-221) with the FUS-DDIT3 translocation.Targeting neoantigens for cancer immunotherapy Domain-swapped T cell receptors improve the safety of TCR gene therapy.Comprehensive adipocytic and neurogenic tissue microarray analysis of NY-ESO-1 expression - a promising immunotherapy target in malignant peripheral nerve sheath tumor and liposarcoma.Surrogate in vitro activation of innate immunity synergizes with interleukin-7 to unleash rapid antigen-driven outgrowth of CD4+ and CD8+ human peripheral blood T-cells naturally recognizing MUC1, HER2/neu and other tumor-associated antigens.Immunotherapy for Esophageal Squamous Cell Carcinoma.Adoptive T-cell therapy: a need for standard immune monitoring.Antigen-specific T cell therapies for cancer.T cells targeting NY-ESO-1 demonstrate efficacy against disseminated neuroblastoma.Adoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen Receptors Reconstructing the immune system with lentiviral vectors.The immune system and cancer evasion strategies: therapeutic concepts.Metastatic soft tissue sarcoma: current treatment landscape and future perspectives.

P2860

Q26771119-EC89D444-EB05-4E85-8ABB-9D7EECB4C7C8 Q26785545-9B10F2D5-0E7F-44D9-8C15-DC159BF99A32 Q26786661-CE28A858-3C68-4AEB-BFC1-FBB52F323FDA Q26797248-0D135D6D-AEF7-4F10-B07E-19B18592B8AC Q26800611-4CEC2186-AA7D-4F1B-B625-563B3EDF0733 Q28068378-4615DD23-E4A3-40C5-8802-DD2D1AE5E369 Q28080312-CD131E45-BB98-4BEC-ABB8-E413F17FFFA8 Q28081611-DFE2A088-2A57-4B90-8C31-44696BF5C770 Q28648164-3B7A21DC-B303-477E-8A38-68C0F1791ED7 Q30251555-A7EFCC93-2DBD-4E68-80CE-CB7CC3A30AC3 Q30253063-3F5D1440-A263-448A-BE6D-6D1677CA8574 Q30491565-CAE02DCA-99A1-40C0-8EC7-4EBA5CDAA492 Q30667174-1CCE2410-FE96-4814-994C-166A09FD5F67 Q34046252-DEC5FCFC-0AE3-4CB5-BA91-A7A264C661F1 Q34470074-D348395A-6E6F-420F-9D20-2F2ABBCE0B68 Q34485950-80296272-5D9D-4FAA-A15E-ED162FF7659D Q35641721-27C64F79-16B4-479F-81F8-3008E8B9D126 Q35980893-3D15502C-9C99-4309-B2A4-1F9DC2C59E6B Q36307671-8A7FA71A-36E8-444B-9BC0-FED878977468 Q36307736-6AA8DF11-804B-43FA-A8F2-D997E78A0822 Q36471557-D39A06D5-DAED-464A-8F91-8B04DFB5ADBD Q36643027-742AF90B-B70C-4CC7-BE1B-4CEC2B7893FE Q36796813-4A567350-A4DF-4A6C-9903-2B8AB93AC312 Q36889067-58CD8ABF-8A9F-4DB7-97CB-8065678BC372 Q36928580-6C197783-6C56-41B1-B950-48A98FF9E4E1 Q37022306-36E6DD55-AF72-4E96-B52F-0B49EBC301C7 Q37100031-8FB82F8B-3FE5-45C4-BB41-4D3B0B974C03 Q37136357-208F5790-CCF7-4267-9741-7BFB26679794 Q37223669-6C8531DE-B352-454D-A213-67B6689A5343 Q37401728-E9DE2868-3F1F-421C-ACE2-6EEA03D51D25 Q37687307-B2DA4EFF-111B-4B7C-83B6-43EBE185D759 Q37706835-8912D3F1-68BE-48D8-A7C0-ABEAA39FC29E Q37730966-399889BA-CFA3-4144-900C-A044A7CD663F Q38525029-464D4C5E-895D-4E1C-9CE3-6F5D36E77743 Q38544740-8857F0E5-21CE-4A93-A64E-60496733A4A9 Q38564461-F660DAA9-55E4-4C63-A26D-E119CE549ABD Q38603686-4DE03ABD-5D9F-4F16-AC62-D86857E62C80 Q38651711-BAADB137-FE87-49C0-BEE5-A58FAB2CCD50 Q38691172-C70FF9DA-91A0-47DD-AA1A-98F99DC7D416 Q38692839-5E61863D-C08F-40BC-8A50-E3C6A37D3E07

P2860

A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response

http://www.wikidata.org/entity/Q35182795

description

2014 nî lūn-bûn

@nan

2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

A pilot trial using lymphocyte ...... p and correlates with response

@ast

A pilot trial using lymphocyte ...... p and correlates with response

@en

type

label

A pilot trial using lymphocyte ...... p and correlates with response

@ast

A pilot trial using lymphocyte ...... p and correlates with response

@en

prefLabel

A pilot trial using lymphocyte ...... p and correlates with response

@ast

A pilot trial using lymphocyte ...... p and correlates with response

@en

P1433

Q35182795-AE1D27B8-6C86-42F6-A6E1-627CA8A17440

P1476

Q35182795-AEB7C534-DBF2-421C-9394-EF85B1536188

P2093

Q35182795-0A8432DD-0E99-4B01-A2CC-B85EA8B3002E

Q35182795-16BFAFEC-D9C4-4A05-A8D1-36EBFBC14D0B

Q35182795-25528B47-C71D-4174-ABAA-41C17BBDE0FE

Q35182795-256745F2-9FCD-4107-9C0E-B19A94163644

Q35182795-36AEEE71-974B-43A2-9F86-FCDCF5D229DA

Q35182795-50C1FD02-A4E2-43E4-AA4A-5315741C7C1F

Q35182795-62A7EAF9-9391-4DF2-899A-849E630752C2

Q35182795-649E9973-7F86-45F6-8EAE-0E204148E5EC

Q35182795-7B0E9ADE-99B2-4D4F-8EB5-5AF211254FB2

Q35182795-9B4FBA8B-D5B8-441C-A3E2-6D97EA0B758E

P2860

Q35182795-06038293-C1AA-45AF-B12A-97840BCE00A8

Q35182795-06F4C138-573C-414A-9059-A0428FD17DBB

Q35182795-25D486B7-9C5C-461E-B5CD-FB84BF9837D5

Q35182795-25FF033A-32B2-4BE5-BF07-C1D9FB19FE52

Q35182795-31D6B433-A3DE-4272-B081-2D39FAAB9EA7

Q35182795-4F2D0D94-3A24-4049-B2AA-7A5A38B41C21

Q35182795-50DF5D50-BC4B-4AE8-9237-0586E1277666

Q35182795-62AB1692-3AA0-4BFC-9537-0F51BAA488E9

Q35182795-636756FF-037A-454D-9895-40E5B7DE4F3D

Q35182795-79BFAA74-F4A3-41DD-B78C-5820FEBF969A

P304

Q35182795-ECAABF0E-0ABA-45D4-BA95-8670B3F0A89A

P31

Q35182795-54CB911D-8000-4501-A9CC-457F554E6E88

P356

Q35182795-2CAD9B43-8850-409E-A603-F6BE12D458C7

P407

Q35182795-F6688F73-1716-4453-BEE7-174E752ACC00

P433

Q35182795-A44D4029-8783-4B0C-BD43-D20DAC3B3C6C

P478

Q35182795-3F6DB2EE-0DE8-4583-B4EA-1782FA7987C5

P50

Q35182795-615FE1B3-3F80-48DC-880D-B66842675415

P577

Q35182795-ADA491FB-7515-4C5D-AACE-4852FD67194D

P698

Q35182795-56D7E427-F495-438E-95AE-18F5CC7696B5

P932

Q35182795-63314414-13FD-49DD-ACE5-4BEA8E0A1769

P356

1078-0432.CCR-14-2708

P1433

Clinical Cancer Research

P1476

A pilot trial using lymphocyte ...... p and correlates with response

@en

P2093

Chyi-Chia R Lee

http://www.w3.org/2001/XMLSchema#string

James C Yang

http://www.w3.org/2001/XMLSchema#string

Jessica S Crystal

http://www.w3.org/2001/XMLSchema#string

John R Wunderlich

http://www.w3.org/2001/XMLSchema#string

Mark E Dudley

http://www.w3.org/2001/XMLSchema#string

Mark Raffeld

http://www.w3.org/2001/XMLSchema#string

Marybeth S Hughes

http://www.w3.org/2001/XMLSchema#string

Mona El-Gamil

http://www.w3.org/2001/XMLSchema#string

Paul F Robbins

http://www.w3.org/2001/XMLSchema#string

Richard A Morgan

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer immunotherapy: moving beyond current vaccines

A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy

Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens

Cancer regression in patients after transfer of genetically engineered lymphocytes

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

P304

1019-1027

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-14-2708

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

Nicholas P. Restifo

P577

2014-12-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25538264

http://www.w3.org/2001/XMLSchema#string

P932

4361810

http://www.w3.org/2001/XMLSchema#string